MD DISPENSING BILL IS LIKELY TO BE DEFERRED FOR MEASURES WITH MORE SENATE INTEREST
Executive Summary
MD DISPENSING BILL IS LIKELY TO BE DEFERRED FOR MEASURES WITH MORE SENATE INTEREST, House Commerce/Health Subcommittee Counsel William Corr indicated at a June 24 session of the midyear meeting of the National Association of Pharmaceutical Manufacturers. Although the legislation (HR 2168) has passed the Health Subcommittee and the full Energy & Commerce Committee, Corr expressed doubts about the bill's future. "It was very controversial in our committee," he noted. "It did pass the committee, [but] I think it probably has seen its end." It is still unclear whether the bill will be considered on the House floor, Corr maintained. Further, the bill has yet to be introduced in the Senate. [The Senate International Trade Subcommittee, chaired by Sen. Matsunaga (D-Hawaii) declined to address MD dispensing during its recent hearings on drug diversion legislation.] "There's a lot [of legislative activity] we've been working on these days, so it's yet to be seen as to whether that legislation gets to the House floor," he said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth